BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY
Volume 21, Issue 12

DOI: 10.58240/1829006X-2025.21.12-140

ORIGINAL RESEARCH

IMMUNOHISTOCHEMISTRY OF BENIGN URINARY BLADDER TUMORS: POLYPS AND PAPILLOMAS

Nizom Ermatov[1], Dilshod Alimuhammedov[2], Ulmas Shodiyev[3], Nargiza Khaydarova[4] , Mamlakat Rustamova[5], Xosiyat Sadullayeva[6], Yulduz Musayeva[7],Ulugbek Shodiyev[8], Ikrom Tilyabov[9], Ikrom Tilyabov[10]

[1]Professor, Department of Children, Adolescents and Nutritional Hygiene Tashkent State Medical University Tashkent, Uzbekistan E-mail: nizom1970@mail.ru
[2]Associate professor, Department of Children, Adolescents and Nutritional Hygiene Tashkent State Medical University Tashkent, Uzbekistan E-mail: dilshod2308@gmail.com https://orcid.org/0000-0003-2824-3760
[3]PhD, Department of Urology, Nephrology and Hemodialysis, Bukhara State Medical Institute, Bukhara, Uzbekistan. https://orcid.org/0009-0007-0016-8574
[4]Department of Forensic Medicine, Bukhara State Medical Institute, Bukhara, Uzbekistan. https://orcid.org/0000-0001-5641-4454
[5]Professor, Department of Internal Medicine No. 2 Tashkent State Medical UniversityTashkent, Uzbekistan
[6]Associate professor, Department of Environmental Hygiene, dotsent Tashkent State Medical University
[7]Professor, Neurology and Medicinal Psychology Tashkent State Medical University Tashkent, Uzbekistan E-mail: yulduz76m@gmail.com
[8]PhD, Neurology and Medicinal Psychology Tashkent State Medical University Tashkent, Uzbekistan
[9]PhD, Associate professor, Department of Human Anatomy and OSTA Tashkent State Medical University Tashkent, Uzbekistan
[10]Assistant, Department of Children, Adolescents and Nutritional Hygiene Tashkent State Medical University Tashkent, Uzbekistan
Corresponding Author: Nizom Ermatov[1]Professor, Department of Children, Adolescents and Nutritional Hygiene Tashkent State Medical UniversityTashkent, Uzbekistan E-mail: nizom1970@mail.ru
Received: Oct 26. 2025; **Accepted**: Nov24, 2025; **Published:** Dec. 29, 2025

Abstract

Benign tumors of the urinary bladder, including polyps and papillomas, are uncommon yet clinically relevant due to their ability to mimic malignant conditions, leading to diagnostic challenges. These lesions can present with symptoms such as hematuria or urinary obstruction, necessitating accurate differentiation from more aggressive pathologies. Immunohistochemistry (IHC) has become a critical diagnostic tool, offering detailed molecular and cellular insights into these tumors. This article explores the immunohistochemical characteristics of benign bladder tumors, with a focus on polyps and papillomas, and highlights their diagnostic and prognostic significance. By examining specific markers, this review underscores the role of IHC in distinguishing benign lesions from malignant counterparts, ultimately guiding appropriate clinical management.

***Keywords*:** Benign bladder tumors, urinary bladder polyps, bladder papillomas, immunohistochemistry, Ki-67

INTRODUCTION

The study of benign urinary bladder tumors, such as polyps and papillomas, has been a focal point of urological and pathological research for decades. These lesions, although non-malignant, present significant diagnostic challenges due to their clinical and histological similarities to malignant urothelial neoplasms. Accurate differentiation is essential to prevent unnecessary aggressive treatments and to ensure appropriate patient management. Immunohistochemistry (IHC) has revolutionized the diagnostic process by enabling the identification of specific molecular markers that characterize these benign lesions, providing a deeper understanding of their biological behavior.

The foundational work in this field has been shaped by the contributions of numerous scientists and researchers. Among the pioneers who systematically categorized the histologic variants of urothelial carcinoma and established key diagnostic criteria for differentiating benign and malignant bladder tumors [1]. Their work laid the groundwork for understanding the morphological and immunohistochemical distinctions between these entities.

The further advanced the field by conducting a

detailed histologic mapping of the urinary bladder's layers [2]. Their research provided critical insights into the localization and behavior of benign lesions, such as polyps and papillomas, and highlighted the importance of understanding tissue architecture in the context of tumor diagnosis. This work has been instrumental in guiding the interpretation of immunohistochemical findings in bladder tumors.

It was made significant contributions by exploring the use of advanced molecular techniques, such as fluorescence in situ hybridization (FISH), alongside immunohistochemistry to differentiate urothelial carcinoma with an inverted growth pattern from inverted papilloma. Their research underscored the value of integrating molecular and immunohistochemical methods to improve diagnostic accuracy, particularly in challenging cases [3].

The expanded the understanding of the molecular origins and pathways involved in urothelial carcinoma, which has indirect implications for the study of benign urothelial lesions [4]. Their work highlighted the importance of molecular markers in understanding tumor biology and provided a framework for investigating the molecular profiles of benign bladder tumors.

Other notable contributors included [5], who investigated the role of cytokeratins and other epithelial markers in the diagnosis of bladder lesions, who explored the utility of p63 and other nuclear markers in distinguishing benign from malignant urothelial proliferations [6]. Additionally, contributed to the understanding of CD44 expression in bladder tumors, emphasizing its role as a marker of urothelial differentiation and its potential diagnostic utility [7].

More recently, updated guidelines on the classification and immunohistochemical characterization of bladder tumors, including benign entities, as part of the World Health Organization (WHO) classification of urinary tract tumors. The work has standardized diagnostic criteria and reinforced the importance of immunohistochemistry in routine pathological practice [8,9].

Collectively, the contributions of these scientists and researchers have significantly advanced our understanding of benign urinary bladder tumors. By identifying and validating specific immunohistochemical markers—such as cytokeratins, p63, Ki-67, CD44, and uroplakins—they have provided tools to distinguish benign polyps and papillomas from malignant lesions. This body of work underscores the importance of integrating immunohistochemistry with traditional histopathological examination to achieve accurate diagnoses and improve patient outcomes.

As the field continues to evolve, the foundational work of these researchers remains critical to our understanding of benign bladder tumors and their immunohistochemical characterization. This article aims to build on their contributions by providing a comprehensive review of the immunohistochemical features of bladder polyps and papillomas, emphasizing their diagnostic and prognostic significance in modern pathology.

Purpose of the Research

The primary purpose of this research is to provide a comprehensive understanding of the immunohistochemical characteristics of benign urinary bladder tumors, specifically polyps and papillomas. These lesions, though non-malignant, often present diagnostic challenges due to their clinical and histological similarities to malignant urothelial neoplasms. Misdiagnosis can lead to unnecessary aggressive treatments, underscoring the need for accurate differentiation.

MATERIALS AND METHODS

This study was designed to investigate the immunohistochemical (IHC) profiles of benign urinary bladder tumors, specifically polyps and papillomas, and to compare them with malignant urothelial lesions. A retrospective analysis was conducted on archival tissue samples from patients diagnosed with benign bladder tumors (polyps and papillomas) and malignant urothelial carcinomas. A total of 50 benign bladder tumor cases (30 polyps and 20 papillomas) and 20 malignant urothelial carcinoma cases were included for comparison.

All tissue samples were fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Serial sections of 4 µm thickness were cut from each block for hematoxylin and eosin (H&E) staining and immunohistochemical analysis. All slides were reviewed by two experienced pathologists to confirm the diagnosis of benign polyps, papillomas, and malignant urothelial carcinomas.

The Ki-67 primary antibodies were used for IHC staining. Positive and negative controls were included for each antibody to ensure staining accuracy. Ki-67: The proliferation index was calculated as the percentage of positively stained nuclei among 500 tumor cells.

The staining patterns of benign tumors were compared with those of malignant lesions to identify diagnostic and prognostic differences.

RESULTS

The immunohistochemical analysis of benign urinary bladder tumors (polyps and papillomas) and their comparison with malignant urothelial carcinomas revealed significant differences in cellular proliferation, as measured by the Ki-67 labeling index. Below, we present the detailed findings related to Ki-67 expression, supported by tables and explanations.

The Ki-67 proliferation index, which reflects the percentage of cells actively undergoing cell division, was evaluated in all cases. The results are summarized in Table 1.

Table 1. Ki-67 Proliferation Index in Benign and Malignant Bladder Tumors

Tumor Type	Mean Ki-67 Index (%)	Range (%)	p-value
Benign Polyps (n=30)	5.2 ± 2.1	2–10	<0.001
Benign Papillomas (n=20)	6.0 ± 1.8	3–9	<0.001
Malignant Carcinomas (n=20)	35.4 ± 10.2	20–55	-

Benign polyps and papillomas exhibited low Ki-67 proliferation indices, with mean values of 5.2% and 6.0%, respectively. This indicates a slow-growing, non-aggressive nature. In contrast, malignant urothelial carcinomas showed significantly higher Ki-67 indices, with a mean of 35.4%, reflecting their high proliferative activity and aggressive behavior. The difference in Ki-67 indices between benign and malignant tumors was statistically significant ($p < 0.001$).

To further understand the proliferation patterns in benign tumors, the distribution of Ki-67 indices was categorized into low (<5%), moderate (5–10%), and high (>10%) groups. The results are presented in Table 2.

Table 2 Distribution of Ki-67 Expression in Benign Tumors

Ki-67 Index Category	Benign Polyps (n=30)	Benign Papillomas (n=20)
Low (<5%)	18 (60.0%)	10 (50.0%)
Moderate (5–10%)	12 (40.0%)	10 (50.0%)
High (>10%)	0 (0.0%)	(0.0%)

The majority of benign polyps (60%) and papillomas (50%) exhibited low Ki-67 indices (<5%), consistent with their indolent nature. The remaining cases showed moderate Ki-67 indices (5–10%), with no cases exceeding 10%. This further supports the classification of these lesions as benign.

A direct comparison of Ki-67 indices between benign and malignant tumors is presented in Table 3.

Table 3 Comparison of Ki-67 Indices Between Benign and Malignant Tumors

Tumor Type	Mean Ki-67 Index (%)	p-value
Benign Tumors (n=50)	5.6 ± 1.9	<0.001
Malignant Tumors (n=20)	± 10.2	-

The mean Ki-67 index for all benign tumors (polyps and papillomas combined) was 5.6%, significantly lower than the mean index of 35.4% observed in malignant tumors. This stark contrast highlights the utility of Ki-67 as a reliable marker for distinguishing benign from malignant bladder lesions.

The Ki-67 proliferation index demonstrated high diagnostic accuracy in differentiating benign from malignant bladder tumors. Using a cutoff value of 10%, the sensitivity and specificity of Ki-67 were calculated as follows:

Sensitivity: 100% (all malignant cases had Ki-67 indices >10%).

Specificity: 100% (all benign cases had Ki-67 indices ≤10%).

The Ki-67 proliferation index is a robust and reliable marker for distinguishing benign urinary bladder tumors (polyps and papillomas) from malignant urothelial carcinomas. The significantly lower Ki-67 indices in benign lesions reflect their slow-growing, non-aggressive nature, while the high indices in malignant tumors underscore their proliferative and aggressive behavior. These findings highlight the diagnostic utility of Ki-67 in the evaluation of bladder tumors, aiding in accurate classification and appropriate patient management.

DISCUSSION

The results of this study demonstrate the significant role of the Ki-67 proliferation index in distinguishing benign urinary bladder tumors (polyps and papillomas) from malignant urothelial carcinomas. The findings reveal a clear dichotomy in cellular proliferation between these two categories of lesions, with benign tumors exhibiting low Ki-67 indices and malignant tumors showing markedly higher indices. This discussion explores the implications of these findings, their alignment with existing literature, and their clinical relevance.

Ki-67 is a well-established marker of cellular proliferation, expressed in all active phases of the cell cycle (G1, S, G2, and M) but absent in resting cells (G0). In this study, benign bladder tumors (polyps and papillomas) consistently demonstrated low Ki-67 indices, with mean values of 5.2% and 6.0%,

respectively. This is consistent with their indolent nature and slow growth rate. In contrast, malignant urothelial carcinomas exhibited significantly higher Ki-67 indices (mean: 35.4%), reflecting their aggressive behavior and high proliferative activity.

These findings align with previous studies that have highlighted the utility of Ki-67 in differentiating benign from malignant lesions in various organs, including the bladder. For example, some researchers have previously reported low Ki-67 indices in benign urothelial lesions, further supporting our results [10,11].

The use of a Ki-67 cutoff value of 10% demonstrated 100% sensitivity and specificity in distinguishing benign from malignant bladder tumors in our study. This high diagnostic accuracy underscores the potential of Ki-67 as a valuable adjunct to histopathological examination, particularly in challenging cases where morphological features alone may be ambiguous.

The diagnostic utility of Ki-67 is further enhanced by its simplicity and reproducibility. Unlike more complex molecular techniques, Ki-67 immunohistochemistry is widely accessible and can be easily integrated into routine diagnostic workflows. This makes it a practical tool for pathologists in both resource-limited and advanced healthcare settings.

The ability to accurately differentiate benign from malignant bladder tumors has significant clinical implications. Misdiagnosis of benign lesions as malignant can lead to unnecessary aggressive treatments, such as radical cystectomy or systemic chemotherapy, which are associated with substantial morbidity and reduced quality of life. Conversely, accurate identification of benign lesions allows for conservative management, such as transurethral resection and regular surveillance, minimizing patient burden.

In addition to its diagnostic role, Ki-67 may also have prognostic value. While this study focused on benign tumors, the high Ki-67 indices observed in malignant tumors are consistent with their aggressive behavior and poor prognosis. Future studies could explore the potential of Ki-67 as a prognostic marker in bladder cancer, particularly in predicting recurrence and progression.

While this study provides valuable insights, it is not without limitations. The retrospective design and relatively small sample size, particularly for rare lesions like papillomas, may limit the generalizability of the findings. Additionally, the study did not evaluate the long-term outcomes of patients with benign tumors, which could provide further insights into the biological behavior of these lesions.

Future research should aim to:

Validate these findings in larger, prospective cohorts.

Investigate the role of Ki-67 in predicting recurrence or progression in benign bladder tumors.

Explore the integration of Ki-67 with other immunohistochemical and molecular markers to enhance diagnostic and prognostic accuracy.

The Ki-67 proliferation index is a powerful and reliable tool for distinguishing benign urinary bladder tumors (polyps and papillomas) from malignant urothelial carcinomas. The significantly lower Ki-67 indices in benign lesions reflect their indolent nature, while the high indices in malignant tumors underscore their aggressive behavior. These findings highlight the diagnostic and potential prognostic utility of Ki-67 in the evaluation of bladder tumors, contributing to improved patient management and outcomes. By integrating Ki-67 immunohistochemistry into routine diagnostic practice, pathologists can enhance the accuracy of bladder tumor classification, ultimately benefiting patients through more tailored and effective treatment strategies.

CONCLUSION

This study underscores the critical role of the Ki-67 proliferation index in the differential diagnosis of benign urinary bladder tumors (polyps and papillomas) and malignant urothelial carcinomas. The findings demonstrate that benign lesions consistently exhibit low Ki-67 indices, reflecting their slow-growing and non-aggressive nature, while malignant tumors show significantly higher Ki-67 indices, indicative of their proliferative and aggressive behavior. The use of a Ki-67 cutoff value of 10% achieved 100% sensitivity and specificity in distinguishing benign from malignant lesions, highlighting its diagnostic utility.

The integration of Ki-67 immunohistochemistry into routine pathological practice offers a simple, reproducible, and highly effective tool for improving diagnostic accuracy. This is particularly valuable in challenging cases where morphological features alone may be ambiguous. Accurate differentiation of benign from malignant bladder tumors is essential to avoid unnecessary aggressive treatments and to ensure appropriate patient management, ultimately enhancing patient outcomes and quality of life.

While this study provides robust evidence supporting the use of Ki-67 in bladder tumor diagnosis, further research is needed to validate these findings in larger, prospective cohorts and to explore the potential prognostic role of Ki-67 in predicting recurrence or progression. By continuing to refine and expand our understanding of immunohistochemical markers like Ki-67, we can advance the field of uropathology and contribute to more personalized and effective patient care.

In conclusion, the Ki-67 proliferation index is a valuable diagnostic tool that enhances the accuracy of bladder tumor classification, supporting clinicians and pathologists in delivering optimal care to patients with urinary bladder lesions.

Acknowledgment

We acknowledge the urologists and clinicians who provided patient data and samples, enabling this study to be conducted with a robust and representative dataset.

We are grateful to the research assistants and students who contributed to data collection, analysis, and organization, ensuring the smooth progress of this project.

Finally, we extend our deepest gratitude to the patients whose participation made this research possible. Their contributions are vital to advancing medical knowledge and improving diagnostic and therapeutic strategies for bladder tumors.

DECLARATIONS .

Funding

This research not funding

Competing Interests

The no competing interests .

REFERENCES

[1] Shodiyev O‘.M. Expression level of ki-67 proliferative marker in cells of urinary bladder polyps and papilloma tissues // British Medical Journal. 2023 Volume-3, № 3. P-7-11 (14.00.00. № 6).

[2] Shodiyev O‘.M., Israilov R.I. Pathogistology of papilloma of the urinary bladder // ART of medicine International Medical Scientific Journal. 2023, Volume 3, № 2. P-52-56 (14.00.00. № 5).

[3] Lopez-Beltran, A., & Cheng, L. (2006). Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Human Pathology, 37(11), 1371-1388. https://doi.org/10.1016/j.humpath.2006.07.002

[4] Paner, G. P., Ro, J. Y., Wojcik, E. M., et al. (2007). Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma. American Journal of Surgical Pathology, 31(9), 1420-1429. https://doi.org/10.1097/PAS.0b013e318058a96b

[5] Jones, T. D., Zhang, S., Lopez-Beltran, A., et al. (2007). Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. American Journal of Surgical Pathology, 31(12), 1861-1867. https://doi.org/10.1097/PAS.0b013e31806841e1

[6] Cheng, L., Davidson, D. D., MacLennan, G. T., et al. (2010). The origins of urothelial carcinoma. Expert Review of Anticancer Therapy, 10(6), 865-880. https://doi.org/10.1586/era.10.73

[7] McKenney, J. K., Gomez, J. A., Desai, S., et al. (2001). Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. American Journal of Surgical Pathology, 25(3), 356-362. https://doi.org/10.1097/00000478-200103000-00009

[8] Harding, M., Patel, P., & Kaye, S. B. (2013). The role of p63 in urothelial carcinoma. Histopathology, 62(6), 827-838. https://doi.org/10.1111/his.12111

[9] Hodges, K. B., Lopez-Beltran, A., MacLennan, G. T., et al. (2010). Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis, and clinical management. BJU International, 107(4), 532-537. https://doi.org/10.1111/j.1464-410X.2010.09765.x

[10] Compérat, E., Larré, S., Roupret, M., et al. (2016). Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Archiv, 468(6), 703-709. https://doi.org/10.1007/s00428-016-1927-8

[11] Lopez-Beltran, A., Cheng, L., & Montironi, R. (2008). Diagnostic and prognostic utility of Ki-67 in bladder cancer. Analytical and Quantitative Cytology and Histology, 30(1), 1-8.